In last trading session, Avalo Therapeutics Inc (NASDAQ:AVTX) saw 0.11 million shares changing hands with its beta currently measuring 0.91. Company’s recent per share price level of $7.03 trading at -$0.48 or -6.39% at ring of the bell on the day assigns it a market valuation of $73.56M. That closing price of AVTX’s stock is at a discount of -390.18% from its 52-week high price of $34.46 and is indicating a premium of 43.81% from its 52-week low price of $3.95. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 89070.0 shares which gives us an average trading volume of 84.23K if we extend that period to 3-months.

For Avalo Therapeutics Inc (AVTX), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 1.50. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.

Avalo Therapeutics Inc (NASDAQ:AVTX) trade information

Upright in the red during last session for losing -6.39%, in the last five days AVTX remained trading in the red while hitting it’s week-highest on Friday, 01/03/25 when the stock touched $7.03 price level, adding 21.8% to its value on the day. Avalo Therapeutics Inc’s shares saw a change of -5.38% in year-to-date performance and have moved -5.38% in past 5-day. Avalo Therapeutics Inc (NASDAQ:AVTX) showed a performance of -30.74% in past 30-days. Number of shares sold short was 22916.0 shares which calculate 0.27 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 35 to the stock, which implies a rise of 79.91% to its current value. Analysts have been projecting 35 as a low price target for the stock while placing it at a high target of 35. It follows that stock’s current price would drop -397.87% in reaching the projected high whereas dropping to the targeted low would mean a loss of -397.87% for stock’s current value.

Avalo Therapeutics Inc (AVTX) estimates and forecasts

Statistics highlight that Avalo Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -43.96% of value to its shares in past 6 months, showing an annual growth rate of 83.27% while that of industry is 16.70. Apart from that, the company came raising its revenue forecast for fiscal year 2025.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 49.49% during past 5 years.